JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 163 filers reported holding JUNO THERAPEUTICS INC in Q4 2015. The put-call ratio across all filers is 2.35 and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $3,994,000 | +2.0% | 87,398 | +0.2% | 0.01% | -7.7% |
| Q3 2017 | $3,914,000 | +50.5% | 87,265 | +0.3% | 0.01% | +44.4% |
| Q2 2017 | $2,600,000 | +24.5% | 87,000 | -7.5% | 0.01% | +28.6% |
| Q1 2017 | $2,088,000 | +17.7% | 94,100 | 0.0% | 0.01% | +16.7% |
| Q4 2016 | $1,774,000 | -35.0% | 94,100 | +3.5% | 0.01% | -40.0% |
| Q3 2016 | $2,728,000 | -21.9% | 90,900 | 0.0% | 0.01% | -23.1% |
| Q2 2016 | $3,494,000 | +1.1% | 90,900 | +0.2% | 0.01% | -7.1% |
| Q1 2016 | $3,455,000 | -11.4% | 90,700 | +2.3% | 0.01% | -12.5% |
| Q4 2015 | $3,900,000 | +10.0% | 88,700 | +1.8% | 0.02% | +6.7% |
| Q3 2015 | $3,544,000 | +498.6% | 87,100 | +684.7% | 0.02% | +650.0% |
| Q2 2015 | $592,000 | -11.2% | 11,100 | +0.9% | 0.00% | -33.3% |
| Q1 2015 | $667,000 | – | 11,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
| Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
| Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
| Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
| BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
| Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
| Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
| ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |